TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK) is pleased to announce that the randomized Phase III clinical trial of TAB008 (Pusintin) has recently reached…
TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and therapies, announced today its…
Granted Subsidy of RMB4 Million TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK) is pleased to announce that the Company, a high-tech enterprise located in…
Suzhou-headquartered biotechnology firm Tot Biopharm has raised $102 million in Series B funding round backed by China Universal GP Ltd and several domestic and foreign investors. In a statement, Tot…
